Pulmonary embolism is one of the most under-diagnosed and over-feared diagnoses in internal medicine — and exactly that paradox makes it a perennial NEET PG favourite. The vignette is unmistakable: post-operative or post-immobilisation patient, sudden dyspnea, pleuritic chest pain, tachycardia, sometimes haemoptysis. The trap is rarely the diagnosis — it is the next step in management, and that depends entirely on hemodynamic stratification.
This NEETPGAI deep dive walks through the Wells score, the PERC rule, D-dimer interpretation pitfalls, CTPA findings, ECG clues, the anticoagulation menu, when to thrombolyse, and the high-yield mistakes examiners chase. Pair it with the antiplatelet and anticoagulant pharmacology guide and the Medicine subject hub.
Pathophysiology and risk factors
Most clinically significant pulmonary emboli arise from deep vein thromboses of the proximal lower limbs (popliteal, femoral, iliac) or pelvic veins. Clot fragments embolise via the right heart and lodge in pulmonary arteries, causing dead-space ventilation, hypoxaemia (V/Q mismatch and shunt), pulmonary hypertension, and acute right ventricular pressure overload — the dominant cause of haemodynamic collapse in massive PE.
Major risk factors (Virchow's triad)
Stasis — prolonged immobilisation, long-haul flights above 4 hours, post-operative state (especially orthopaedic — hip and knee arthroplasty), pregnancy and puerperium.
Hypercoagulability — malignancy (Trousseau syndrome — migratory thrombophlebitis), antiphospholipid syndrome, factor V Leiden, prothrombin G20210A, protein C/S/antithrombin deficiency, oral contraceptives plus smoking, hormone replacement, COVID-19, nephrotic syndrome.
Indian context: post-partum and post-caesarean PE is disproportionately common given the high birth rate and inconsistent prophylaxis in district hospitals; tuberculosis-related immobilisation and hospital-acquired DVT are growing causes.
Clinical features
The classic triad of dyspnea, pleuritic chest pain, and haemoptysis appears in fewer than 20 percent of cases. More common presentations are sudden unexplained dyspnea, tachycardia, syncope (massive PE — about 10 percent), or unilateral leg swelling.
Examination findings:
Tachypnea (most common physical sign — over 90 percent).
Tachycardia (about 40 percent).
Loud P2, fixed splitting of S2, right-sided S3 or S4.
Hypotension and shock in massive PE.
DVT signs in only about 25 percent — absent leg findings do NOT rule out PE.
Pretest probability — Wells, Geneva, PERC
Modified Wells score
Criterion
Points
Clinical signs of DVT
3.0
PE more likely than alternative
3.0
Heart rate above 100
1.5
Immobilisation or surgery within 4 weeks
1.5
Previous DVT/PE
1.5
Haemoptysis
1.0
Active malignancy
1.0
Two-tier interpretation: PE unlikely if 4 or below, PE likely if above 4. Three-tier: low under 2, moderate 2 to 6, high above 6.
PERC rule (Pulmonary Embolism Rule-out Criteria)
If a low-pretest-probability patient meets ALL eight PERC criteria, PE is ruled out without D-dimer:
Age under 50.
Heart rate under 100.
SpO2 at or above 95 percent.
No haemoptysis.
No estrogen use.
No prior DVT/PE.
No unilateral leg swelling.
No surgery or trauma in last 4 weeks requiring hospitalisation.
PERC is only valid in low-pretest-probability patients (under 15 percent prevalence).
D-dimer interpretation
D-dimer is highly sensitive but poorly specific. Use it only when pretest probability is low or intermediate. Cutoffs:
Standard high-sensitivity ELISA — under 500 ng/mL (FEU) rules out PE.
Age-adjusted cutoff (above 50 years) — age multiplied by 10 ng/mL. A 70-year-old with D-dimer 650 is still considered negative.
YEARS algorithm — three items (DVT signs, haemoptysis, PE most likely). If zero items, D-dimer cutoff is 1000 ng/mL; if at least one item, cutoff is 500 ng/mL.
False positives are rampant: pregnancy, sepsis, recent surgery, trauma, malignancy, inflammation, age over 80.
Imaging
CT pulmonary angiography (CTPA)
CTPA is the first-line confirmatory test in most centres. Findings:
Filling defect in pulmonary artery (lobar, segmental, or subsegmental).
Mosaic perfusion pattern.
Wedge-shaped pleural-based infarct (Hampton hump on CXR equivalent).
RV-to-LV diameter ratio above 1.0 — suggests RV strain and worse prognosis.
Ventilation-perfusion (V/Q) scan
Indicated when CTPA is contraindicated (renal failure, contrast allergy, pregnancy in first trimester preferred). High-probability scan (multiple unmatched segmental defects) plus high pretest probability has 96 percent specificity.
Other imaging
Compression ultrasound of legs — confirms DVT in 30 to 50 percent of PE patients; positive ultrasound plus suggestive symptoms is enough to start anticoagulation.
Echocardiography — RV dilation, McConnell sign (akinesia of mid-free wall with normal apex — relatively specific for acute PE), tricuspid regurgitation, septal flattening. Bedside echo is useful in unstable patients before transport for CTPA.
Massive (high-risk) PE — alteplase 100 mg IV over 2 hours OR 0.6 mg/kg IV bolus over 15 minutes if cardiac arrest. Class I recommendation.
Intermediate-high risk — case-by-case; if patient deteriorates on anticoagulation alone, give thrombolysis (PEITHO trial showed reduced collapse but increased bleeding).
Catheter-directed thrombolysis (low-dose alteplase via pulmonary artery catheter) — emerging alternative with lower systemic bleeding risk.
Surgical embolectomy — for failed thrombolysis or contraindication; needs cardiothoracic surgery setup.
Absolute contraindications to thrombolysis — recent intracranial haemorrhage, active internal bleeding, recent stroke, recent CNS surgery, recent major trauma.
IVC filter
Indicated only when anticoagulation is contraindicated (active major bleeding) or for recurrent PE despite therapeutic anticoagulation. Retrievable filters preferred; remove once anticoagulation can be resumed.
Post-PE syndrome and chronic complications
Up to 40 percent of patients have persistent dyspnea or reduced exercise tolerance after acute PE. About 2 to 4 percent develop chronic thromboembolic pulmonary hypertension (CTEPH) — confirmed by V/Q mismatch on V/Q scan, mean PA pressure at or above 25 mmHg at right heart catheterisation. CTEPH is potentially curable by pulmonary endarterectomy at specialised centres.
NEET PG MCQ traps
Massive PE with cardiac arrest — give alteplase 50 mg bolus during CPR; do NOT delay for confirmatory CTPA.
Pregnancy with suspected PE — V/Q scan is preferred over CTPA in first trimester (lower fetal radiation); compression ultrasound is the safest first step if DVT signs are present.
Wells score above 4 — go directly to CTPA, skip D-dimer.
PERC negative — no further testing needed; PE excluded clinically.
DOAC choice in cancer — DOACs preferred unless GI cancer; this is a 2024 update from earlier LMWH-first practice.
Saddle embolus — large clot at pulmonary artery bifurcation; almost always massive PE; needs urgent thrombolysis or surgical embolectomy.
McConnell sign — RV free-wall akinesia with apical sparing; relatively specific for acute PE.
Antiphospholipid syndrome — warfarin, NOT DOAC. INR target 2 to 3 (some advocate 3 to 4 in arterial events).
Heparin-induced thrombocytopenia (HIT) — switch to argatroban, bivalirudin, or fondaparinux. Never give platelets routinely.
Paradoxical embolism — stroke or systemic embolism with PE; suggests right-to-left shunt (PFO, ASD).
CHEST 2021 anticoagulation guideline — DOACs preferred over warfarin for most VTE.
Caravaggio trial (2020) — apixaban non-inferior to LMWH for cancer-associated VTE without increased major bleeding except GI.
NICE 2023 update — apixaban and rivaroxaban first-line for VTE.
Indian context — the cost of brand-name DOACs is approximately 20 to 40 times generic warfarin, but Indian generics of apixaban and rivaroxaban have closed the gap. Still, INR-monitored warfarin remains common in district hospitals where coagulation lab access is intermittent. Post-partum VTE prophylaxis with LMWH is mandated in tertiary centres but inconsistently applied; this is a growing FMGE and NEXT-style vignette.
Frequently asked questions
When should D-dimer be ordered in suspected PE?
D-dimer is ordered only when pretest probability is low or intermediate by Wells or revised Geneva score. A negative high-sensitivity D-dimer (below 500 ng/mL, or age-adjusted cutoff above 50) effectively rules out PE in low-risk patients. Do not order D-dimer in high-probability patients — go directly to CTPA.
What is the YEARS algorithm and age-adjusted D-dimer?
The YEARS algorithm uses three criteria (clinical signs of DVT, hemoptysis, PE most likely diagnosis). If none are present, a D-dimer below 1000 ng/mL rules out PE. Age-adjusted cutoff is age multiplied by 10 ng/mL for patients above 50, increasing specificity without compromising sensitivity.
When is thrombolysis indicated in pulmonary embolism?
Systemic thrombolysis (alteplase 100 mg over 2 hours) is indicated for massive (high-risk) PE with sustained hypotension below 90 mmHg systolic or shock. In intermediate-high risk (submassive) PE with RV strain plus elevated troponin, thrombolysis is considered case-by-case if the patient deteriorates. Catheter-directed thrombolysis is an alternative with lower bleeding risk.
Which DOAC is preferred for PE in cancer patients?
For PE associated with active cancer, current guidelines recommend a DOAC (apixaban, rivaroxaban, or edoxaban) over LMWH for most patients. LMWH is preferred over DOACs in luminal gastrointestinal malignancy due to bleeding risk. Treatment is for at least 6 months and continued indefinitely while cancer is active.
What ECG findings suggest pulmonary embolism?
Sinus tachycardia is the most common ECG finding (in about 40 percent). Classic but uncommon (10 to 15 percent) is the S1Q3T3 pattern — deep S in lead I, Q wave and inverted T in lead III. Right axis deviation, new right bundle branch block, T-wave inversion in V1 to V4 (RV strain), and atrial fibrillation are also recognised.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: May 2026
